
ASND
256.84 USD
-1.24%
Today
-1.65%
1D
Market is open
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Ascendis Pharma A/S
Currency
USD
Market Cap
17.10B
Avg Daily Volume
706.55K
52 Week High
282.15 USD
52 Week Low
188.071 USD
Trading Hours
See hours
Business Summary
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Top News
Ascendis
+6.74%
Weekly Recap: Orphan status backed and Germany launch planned for Q1 2027
tradingview.com
1d ago

Ascendis
+6.74%
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
finance.yahoo.com
4d ago

Ascendis
+6.74%
Ascendis Pharma A/S (ASND) Receives Positive EU Orphan Designation Opinion
tradingview.com
4d ago

Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.

